Angiotensin-converting enzyme inhibitor therapy for ventricular dysfunction in infants, children and adolescents: a review

• Published in: Progress in pediatric cardiology 2000-11, Vol.12 (1), p.91-111
• Main Authors: Grenier, Michelle A, Fioravanti, Joanne, Truesdell, Susie C, Mendelsohn, Alan M, Vermilion, Roger P, Lipshultz, Steven E
• Format: Article
• Language: English
• Subjects: ACE inhibition; Afterload reduction; Congenital heart disease; Congestive heart failure; Pediatric; Ventricular dysfunction
• ISSN: 1058-9813; 1558-1519
• DOI: 10.1016/S1058-9813(00)00061-8

Angiotensin-converting enzyme (ACE) inhibitors have become an important part of the pharmacologic armamentarium in the battle against treatment of ventricular dysfunction. There have been a number of large controlled, randomized trials in adults with both asymptomatic and symptomatic ventricular dysfunction, which confirm the safety and efficacy of this category of drugs for the treatment of this potentially lethal condition. ACE inhibitors may be used to treat infants, children and adolescents with asymptomatic and symptomatic ventricular dysfunction as well. The data supporting their use in children is less complete than that concerning the treatment of adults. We review here the various causes of ventricular dysfunction and congestive heart failure (CHF) in infants, children, and adolescents; the data available regarding treatment of these conditions with ACE inhibitors, and the safety and efficacy of these drugs for the various conditions. The pharmacokinetics and proposed mechanisms of action of ACE inhibitors in children are reviewed, as are speculated long-term results of ACE inhibitor use in cohorts of growing children. Recommendations are made for future studies.